Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design

Detalles Bibliográficos
Autores principales: Krown, Susan E, Fingleton, Barbara, Lee, Jeannette Y, Egorin, Merrill J, Koon, Henry B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Meeting Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002724/
http://dx.doi.org/10.1186/1750-9378-5-S1-A62
_version_ 1782193772270977024
author Krown, Susan E
Fingleton, Barbara
Lee, Jeannette Y
Egorin, Merrill J
Koon, Henry B
author_facet Krown, Susan E
Fingleton, Barbara
Lee, Jeannette Y
Egorin, Merrill J
Koon, Henry B
author_sort Krown, Susan E
collection PubMed
description
format Text
id pubmed-3002724
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30027242010-12-16 Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design Krown, Susan E Fingleton, Barbara Lee, Jeannette Y Egorin, Merrill J Koon, Henry B Infect Agent Cancer Meeting Abstracts BioMed Central 2010-10-11 /pmc/articles/PMC3002724/ http://dx.doi.org/10.1186/1750-9378-5-S1-A62 Text en Copyright ©2010 Krown et al; licensee BioMed Central Ltd.
spellingShingle Meeting Abstracts
Krown, Susan E
Fingleton, Barbara
Lee, Jeannette Y
Egorin, Merrill J
Koon, Henry B
Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title_full Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title_fullStr Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title_full_unstemmed Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title_short Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
title_sort phase ii aids malignancy consortium (amc) trial of topical halofuginone in aids-associated kaposi’s sarcoma (ks): clinical and biological effects using a novel intra-patient control design
topic Meeting Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002724/
http://dx.doi.org/10.1186/1750-9378-5-S1-A62
work_keys_str_mv AT krownsusane phaseiiaidsmalignancyconsortiumamctrialoftopicalhalofuginoneinaidsassociatedkaposissarcomaksclinicalandbiologicaleffectsusinganovelintrapatientcontroldesign
AT fingletonbarbara phaseiiaidsmalignancyconsortiumamctrialoftopicalhalofuginoneinaidsassociatedkaposissarcomaksclinicalandbiologicaleffectsusinganovelintrapatientcontroldesign
AT leejeannettey phaseiiaidsmalignancyconsortiumamctrialoftopicalhalofuginoneinaidsassociatedkaposissarcomaksclinicalandbiologicaleffectsusinganovelintrapatientcontroldesign
AT egorinmerrillj phaseiiaidsmalignancyconsortiumamctrialoftopicalhalofuginoneinaidsassociatedkaposissarcomaksclinicalandbiologicaleffectsusinganovelintrapatientcontroldesign
AT koonhenryb phaseiiaidsmalignancyconsortiumamctrialoftopicalhalofuginoneinaidsassociatedkaposissarcomaksclinicalandbiologicaleffectsusinganovelintrapatientcontroldesign

Ejemplares similares